Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma

por Azuaje, Francisco, Tiemann, Katja, Niclou, Simone P
Publicado 2015

Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM)

por Demeure, Kevin, Fack, Fred, Duriez, Elodie, Tiemann, Katja, Bernard, Amandine, Golebiewska, Anna, Bougnaud, Sébastien, Bjerkvig, Rolf, Domon, Bruno, Niclou, Simone P.
Publicado 2016

Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF

por Podergajs, Neza, Brekka, Narve, Radlwimmer, Bernhard, Herold-Mende, Christel, Talasila, Krishna M., Tiemann, Katja, Rajcevic, Uros, Lah, Tamara T., Bjerkvig, Rolf, Miletic, Hrvoje
Publicado 2013

The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status

por Johansson, Mikael, Oudin, Anaïs, Tiemann, Katja, Bernard, Amandine, Golebiewska, Anna, Keunen, Olivier, Fack, Fred, Stieber, Daniel, Wang, Baofeng, Hedman, Håkan, Niclou, Simone P.
Publicado 2013

The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein–protein interaction in glioblastoma

por Neirinckx, Virginie, Hau, Ann-Christin, Schuster, Anne, Fritah, Sabrina, Tiemann, Katja, Klein, Eliane, Nazarov, Petr V, Matagne, André, Szpakowska, Martyna, Meyrath, Max, Chevigné, Andy, Schmidt, Mirko H H, Niclou, Simone P
Publicado 2019